Avacta Group appoint Paul Fry as Non Executive Director

Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced the appointment of Paul Fry as Non Executive Director with effect from 3 February 2020.

Paul has extensive financial experience across a number of industries including biotech, pharmaceutical and telecommunications.  He is currently Chief Financial Officer of Vectura Group plc, an industry leading inhaled drug delivery specialist listed on the FTSE Main Market.  

Prior to his current position, he was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor technology.  Paul has also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GlaxoSmithKline (“GSK”), where he held a number of senior roles including Head of Global Finance Services and Chief Financial Officer for GSK’s Italian pharmaceutical business.

Paul will be appointed Chair of the Audit Committee.

Dr Eliot Forster, Chairman of Avacta Group, commented:

“I am delighted to welcome Paul to the Board of Avacta.  Paul has significant financial and commercial experience in the pharmaceutical and biotech sector and his appointment reflects our commitment to attracting the best talent to the Company.  We look forward to working with him as Avacta develops into a clinical stage biotechnology company.”

Paul Fry, Non Executive Director of Avacta Group, commented:

“I am excited by the opportunity to work with Avacta in their mission to develop novel cancer immunotherapies and to commercialise the Affimer technology in other markets.  I look forward to helping support the evolution of the Company and realising value for both patients and shareholders.”

Regulatory disclosure

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Paul Andrew Fry, 53, holds nil ordinary shares in the Company. Mr. Fry’s current and previous directorships are as follows:

Current Directorships/Partnerships:

Vectura Group plc

Directorships/Partnerships held in last 5 years:

None

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Avacta plc notice regarding publication error

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta Group Plc

Avacta inks radiopharma deal with POINT Biopharma

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals.  The radiopharmaceutical market is expected to grow

Avacta Group Plc

Avacta signs new cancer therapy deal

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group Plc

Research looks to improve wastewater testing for COVID-19

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Avacta Group Plc

Hopes for clinical trial on humans of tumour targeting drug

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group Plc

BioSpace global roundup

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Avacta Group Plc

Talks could trigger COVID test rollout

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is